Publicaciones (11) Publicaciones de Sara García Alonso

2022

  1. KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors

    Molecular Oncology, Vol. 16, Núm. 17, pp. 3066-3081

  2. mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer

    Molecular Cancer Research, Vol. 20, Núm. 7, pp. 1108-1121

2021

  1. Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  2. RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression

    Cancer Cell

2018

  1. Refining Early Antitumoral Drug Development

    Trends in Pharmacological Sciences

  2. Resistance to antibody–drug conjugates

    Cancer Research, Vol. 78, Núm. 9, pp. 2159-2165

2017

  1. Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer

    Clinical Cancer Research, Vol. 23, Núm. 22, pp. 7006-7019

  2. Resistance to the antibody–drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity

    Cancer Research, Vol. 77, Núm. 17, pp. 4639-4651

2016

  1. Multisite phosphorylation of P-Rex1 by protein kinase C

    Oncotarget, Vol. 7, Núm. 47, pp. 77937-77949

2015

  1. Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling

    Oncotarget, Vol. 6, Núm. 30, pp. 30057-30071

  2. P73 is required for endothelial cell differentiation, migration and the formation of vascular networks regulating VEGF and TGFβ signaling

    Cell Death and Differentiation, Vol. 22, Núm. 8, pp. 1287-1299